Close Menu

NEW YORK (GenomeWeb) – Genentech will sequence the whole genomes of 3,000 people from 23andMe's Parkinson's disease community in an effort to identify drug targets, the companies announced today.

Under the terms of the deal, 23andMe will be able to conduct additional research on the generated data once the project is completed. Additionally, 23andMe can share the data, scrubbed of patients' identifying information, with other researchers. Only data from 23andMe customers who have consented to participate in the research will be shared, 23andMe said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.